Thus, the authors claim to have investigated the protective effects of pretreatment with diazoxide against myocardial stunning, produced by 20 minutes of no-flow global ischemia in isolated buffer-perfused hearts. However, stunning is defined as reversible myocardial dysfunction that persists after a brief period of ischemia despite full reperfusion. In isolated buffer-perfused rodent hearts, 20 minutes of ischemia already results in significant cardiac necrosis. For instance, 20 minutes of global cardiac ischemia in mice resulted in 24Ϯ4% necrosis of the left ventricle. 2 As an unfortunate consequence of this, the diazoxide-induced improvement in recovery of left ventricular contractile function (during the subsequent 60 minutes of reperfusion) in the wild-type control mice cannot simply be ascribed to attenuation of stunning, because it could also have resulted from limitation of myocardial infarct size. 3, 4 The authors should therefore have chosen a brief period of ischemia (Ͻ10 minutes) that results in pure stunning without infarction. 5 In such a protocol, an additional group that received diazoxide just before reperfusion would have allowed further delineation between antiischemic and possible reperfusion injury-limiting effects of diazoxide in stunning.
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Alternatively, the authors could have supported their conclusions by demonstrating a lack of effect of diazoxide on infarct size. This is, however, unlikely in view of the reported infarct size-limiting effect of diazoxide in mice. 4 Rather, studying additional groups subjected to a long period of ischemia (Ն20 minutes) would have allowed assessment of the involvement of mitochondrial versus sarcolemmal K ϩ ATP channels in the infarct size-limiting effects of diazoxide. 3, 4 Finally, diazoxide was administered in a concentration of 100 mol/L. A concentration of 30 mol/L may already produce a maximal effect, and a further increase to 100 mol/L may be associated with loss of mitochondrial K ϩ ATP channel selectivity. 3, 4 Hence, studying doses of 30 and 100 mol/L in both brief and long ischemia protocols would have provided valuable additional information on the role of mitochondrial versus sarcolemmal K ϩ ATP channels in the protection by diazoxide against reversible and irreversible myocardial damage in mice. 
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Our study was conducted to determine whether diazoxideinduced protective effect on the ischemia-induced contractile dysfunction could be observed in the heart of sarcolemmal K ATP channel-deficient mice. The findings of the study suggested that activation of sarcolemmal K ATP channels rather than mitochondrial K ATP channels is important for the cardioprotective effect of diazoxide in mouse hearts. 1 We measured the left ventricular function during 20-minute ischemia followed by 60-minute reperfusion and found that diazoxide improved the contractile dysfunction in wildtype but not Kir6.2 knockout hearts. The stunned myocardium is defined as "prolonged postischemic contractile dysfunction of myocardium salvaged by reperfusion." 2 As pointed out by Duncker and Verdouw, the 20-minute global ischemia might have produced irreversible as well as reversible myocardial damage in isolated mouse hearts. The discrimination between reversible and irreversible injuries could not be determined with certainty because we did not conduct histopathological evaluation in the study. 1 However, our study was conducted to determine whether diazoxide could produce cardioprotection in sarcolemmal K ATP channel-deficient hearts rather than to evaluate the effects of diazoxide on purely reversible myocardial damage.
We believe that the concentration of diazoxide used in our study (100 mol/L) might not be too high. Liu et al 3 reported that diazoxide induced reversible oxidation of flavoprotein, an index of mitochondrial K ATP channel activation, with an EC 50 of 27 mol/L in rabbit ventricular cells, and the maximum response could be obtained with 100 mol/L. They showed that diazoxide at this concentration failed to activate sarcolemmal K ATP channels in physiological conditions. 3 Our study, 1 however, showed that diazoxide could activate sarcolemmal K ATP channels in a diseased state, possibly with increased ADP level in the cytosol, indicating that the beneficial effects of diazoxide on ischemic myocardium must be interpreted with caution, at least with regard to mouse hearts. 
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